Black Diamond Therapeutics (BDTX) Free Cash Flow (2019 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Free Cash Flow came in at -$10.2 million in Q1 2026, down 119.06% YoY from $53.5 million in Q1 2025, and down 51.09% on a QoQ basis from -$6.7 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Free Cash Flow (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 8 years of Free Cash Flow data on file, last reported at -$10.2 million in Q1 2026.
- Quarterly Free Cash Flow fell 119.06% year-over-year to -$10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.9 million (down 379.75% YoY) and the FY2025 annual result came in at $29.8 million, up 147.62% from the prior year.
- Free Cash Flow eased to -$10.2 million in Q1 2026, from -$6.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $53.5 million in Q1 2025 to a low of -$28.6 million in Q1 2022.
- A 5-year average of -$11.5 million and a median of -$15.0 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2025 — Free Cash Flow soared 352.15% — and 2026, when it tumbled 119.06%.
- Tracing BDTX's Free Cash Flow over 5 years: stood at -$21.9 million in 2022, then soared by 36.24% to -$14.0 million in 2023, then dropped by 7.31% to -$15.0 million in 2024, then surged by 55.08% to -$6.7 million in 2025, then tumbled by 51.09% to -$10.2 million in 2026.
- The last three Free Cash Flow figures came in at -$10.2 million (Q1 2026), -$6.7 million (Q4 2025), and -$7.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | -8.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.22 Mn |
| Jun 30, 2026 | -8.22 Mn |
| Mar 31, 2026 | -10.19 Mn |
| Mar 31, 2026 | -10.19 Mn |
| Dec 31, 2025 | -6.74 Mn |
| Dec 31, 2025 | -6.74 Mn |
| Sep 30, 2025 | -7.81 Mn |
| Sep 30, 2025 | -7.81 Mn |
| Jun 30, 2025 | -9.12 Mn |
| Jun 30, 2025 | -9.12 Mn |
| Mar 31, 2025 | 53.45 Mn |
| Mar 31, 2025 | 53.45 Mn |
| Dec 31, 2024 | -15.01 Mn |
| Dec 31, 2024 | -15.01 Mn |
| Sep 30, 2024 | -11.28 Mn |
| Sep 30, 2024 | -11.28 Mn |
| Jun 30, 2024 | -15.06 Mn |
| Jun 30, 2024 | -15.06 Mn |
| Mar 31, 2024 | -21.20 Mn |
| Mar 31, 2024 | -21.20 Mn |